What is BioCryst Pharmaceuticals's deferred revenue?

BioCryst Pharmaceuticals (BCRX) reported deferred revenue of $5.41M in Q1 2026.

What is the long-term trend for BioCryst Pharmaceuticals's deferred revenue?

Over 4 years (2020 to 2025), BioCryst Pharmaceuticals's deferred revenue has grown at a -100.0% compound annual growth rate (CAGR), from $150K to $0.

What does deferred revenue mean?

Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.

BioCryst Pharmaceuticals BCRX Deferred Revenue

Deferred Revenue at other companies

Ionis PharmaceuticalsIONS

$69.2M-14.7%

BridgeBio PharmaBBIO

$6.12M-65.1%

Arrowhead ResearchARWR

$108.54M+151%

ALN

Alnylam PharmaceuticalsALNY

$3.21M-88.6%

PrecigenPGEN

$410K-25.3%

CRISPR TherapeuticsCRSP

$15.34M+408%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's deferred revenue?: BioCryst Pharmaceuticals (BCRX) reported deferred revenue of $5.41M in Q1 2026.
What is the long-term trend for BioCryst Pharmaceuticals's deferred revenue?: Over 4 years (2020 to 2025), BioCryst Pharmaceuticals's deferred revenue has grown at a -100.0% compound annual growth rate (CAGR), from $150K to $0.
What does deferred revenue mean?: Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.